Pro Medicus Valuation
Is PME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PME (A$214.62) is trading above our estimate of fair value (A$38.22)
Significantly Below Fair Value: PME is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PME?
Key metric: As PME barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is PME's PB Ratio? | |
|---|---|
| PB Ratio | 119.5x |
| Book | AU$187.73m |
| Market Cap | AU$22.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 137.9x |
| Enterprise Value/EBITDA | 197x |
| PEG Ratio | 14.2x |
Price to Book Ratio vs Peers
How does PME's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.4x | ||
COH Cochlear | 10.4x | 11.7% | AU$19.2b |
MDR MedAdvisor | 3.2x | 69.1% | AU$165.4m |
ONE Oneview Healthcare | 25.3x | 43.6% | AU$212.4m |
CGS Cogstate | 2.7x | 6.6% | AU$170.8m |
PME Pro Medicus | 119.5x | 19.1% | AU$22.4b |
Price-To-Book vs Peers: PME is expensive based on its Price-To-Book Ratio (119.5x) compared to the peer average (10.4x).
Price to Book Ratio vs Industry
How does PME's PB Ratio compare vs other companies in the AU Healthcare Services Industry?
| 0 Companies | Price / Book | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: PME is expensive based on its Price-To-Book Ratio (119.5x) compared to the Global Healthcare Services industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is PME's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 119.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate PME's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$214.62 | AU$152.71 -28.8% | 32.4% | AU$255.00 | AU$37.00 | n/a | 14 |
| Nov ’25 | AU$195.80 | AU$142.85 -27.0% | 27.5% | AU$200.00 | AU$37.00 | n/a | 14 |
| Oct ’25 | AU$180.61 | AU$136.42 -24.5% | 24.7% | AU$193.00 | AU$37.00 | n/a | 14 |
| Sep ’25 | AU$150.70 | AU$128.25 -14.9% | 27.0% | AU$160.00 | AU$37.00 | n/a | 15 |
| Aug ’25 | AU$144.32 | AU$106.81 -26.0% | 28.4% | AU$152.68 | AU$34.50 | n/a | 15 |
| Jul ’25 | AU$135.66 | AU$104.34 -23.1% | 28.4% | AU$152.68 | AU$34.50 | n/a | 15 |
| Jun ’25 | AU$120.12 | AU$102.54 -14.6% | 28.7% | AU$152.68 | AU$34.50 | n/a | 15 |
| May ’25 | AU$109.25 | AU$95.57 -12.5% | 29.7% | AU$152.68 | AU$34.50 | n/a | 15 |
| Apr ’25 | AU$103.75 | AU$88.64 -14.6% | 24.7% | AU$120.00 | AU$34.50 | n/a | 14 |
| Mar ’25 | AU$103.39 | AU$88.64 -14.3% | 24.7% | AU$120.00 | AU$34.50 | n/a | 14 |
| Feb ’25 | AU$100.64 | AU$77.32 -23.2% | 19.6% | AU$100.00 | AU$34.50 | n/a | 12 |
| Jan ’25 | AU$95.83 | AU$78.14 -18.5% | 19.0% | AU$100.00 | AU$34.50 | n/a | 13 |
| Dec ’24 | AU$88.06 | AU$73.52 -16.5% | 22.5% | AU$90.00 | AU$34.50 | n/a | 13 |
| Nov ’24 | AU$78.40 | AU$71.99 -8.2% | 22.0% | AU$88.80 | AU$34.50 | AU$195.80 | 13 |
| Oct ’24 | AU$83.39 | AU$71.61 -14.1% | 22.3% | AU$88.80 | AU$33.50 | AU$180.61 | 13 |
| Sep ’24 | AU$72.96 | AU$67.29 -7.8% | 21.2% | AU$80.00 | AU$31.00 | AU$150.70 | 13 |
| Aug ’24 | AU$69.02 | AU$61.68 -10.6% | 20.8% | AU$79.33 | AU$30.00 | AU$144.32 | 13 |
| Jul ’24 | AU$65.64 | AU$59.24 -9.8% | 20.2% | AU$79.33 | AU$30.00 | AU$135.66 | 13 |
| Jun ’24 | AU$61.65 | AU$58.04 -5.9% | 19.3% | AU$71.00 | AU$30.00 | AU$120.12 | 12 |
| May ’24 | AU$60.48 | AU$59.41 -1.8% | 17.8% | AU$71.00 | AU$28.50 | AU$109.25 | 11 |
| Apr ’24 | AU$63.87 | AU$59.41 -7.0% | 17.8% | AU$71.00 | AU$28.50 | AU$103.75 | 11 |
| Mar ’24 | AU$60.90 | AU$56.65 -7.0% | 21.2% | AU$71.00 | AU$28.50 | AU$103.39 | 12 |
| Feb ’24 | AU$65.37 | AU$54.03 -17.4% | 20.4% | AU$71.00 | AU$30.00 | AU$100.64 | 12 |
| Jan ’24 | AU$55.26 | AU$53.76 -2.7% | 20.3% | AU$71.00 | AU$30.00 | AU$95.83 | 12 |
| Dec ’23 | AU$59.70 | AU$52.90 -11.4% | 19.6% | AU$68.71 | AU$30.00 | AU$88.06 | 11 |
| Nov ’23 | AU$57.11 | AU$52.72 -7.7% | 20.5% | AU$68.71 | AU$28.00 | AU$78.40 | 11 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
SDI
AU$122.4m
Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.
SDI
AU$1.02
7D
0%
1Y
22.9%
Doctor Care Anywhere Group
AU$25.7m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.065
7D
-3.0%
1Y
32.7%
Nova Eye Medical
AU$36.6m
Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.
EYE
AU$0.16
7D
3.2%
1Y
14.3%